Previous Article | Next Article 
Infection and Immunity, June 2001, p. 4177-4179, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.4177-4179.2001
Differential V
T-Cell Receptor Usage during
Chronic Experimental Schistosomiasis Corresponds with Distinct
Pathological Presentations
W. Evan
Secor* and
George L.
Freeman Jr.
Immunology Branch, Division of Parasitic Diseases,
National Center for Infectious Diseases, Centers for Disease Control
and Prevention, Public Health Service, U.S. Department of Health and
Human Services, Atlanta, Georgia 30341-3724
Received 16 January 2001/Returned for modification 6 March
2001/Accepted 16 March 2001
 |
ABSTRACT |
CBA/J male mice with chronic Schistosoma mansoni
infections display either moderate splenomegaly syndrome (MSS) or
hypersplenomegaly syndrome (HSS). As MSS and HSS mice differ in several
immunologic characteristics, we investigated T-cell receptor V
usage. The groups had significantly different expression of several
V
s, suggesting a relationship between the T-cell repertoire and
schistosomiasis pathology.
 |
TEXT |
Chronic (20-week) infection of CBA/J
male mice with Schistosoma mansoni results in development of
two distinct pathologies that closely parallel those of humans with
chronic schistosomiasis (4). Moderate splenomegaly
syndrome (MSS) is analogous to the less severe human intestinal form of
the disease. Hypersplenomegaly syndrome (HSS) in mice resembles the
more severe human hepatosplenic disease form and is characterized by
periportal liver fibrosis, extreme splenomegaly, profound anemia,
cachexia, ascites, and thymic atrophy.
In addition to these differences in pathology, mice with MSS and HSS
disease forms also differ extensively in regard to their immune
responses. HSS mice produce more tumor necrosis factor alpha and less
antigen-specific interleukin 10 (1, 2), produce lower
levels of Th1-associated antibody isotypes specific for schistosome
antigens (3, 7), and display higher levels of cell
activation markers (3) than MSS mice. However, the most compelling immunologic evidence linking this murine model to responses in human schistosomiasis is the parallel production of certain anti-schistosome soluble egg antigen (SEA) antibodies in mice and in
humans with the less severe disease form (6). These distinct antisoluble egg antigen antibodies express characteristic idiotypes (Id) that are produced by MSS (but not HSS) mice and by
humans with the intestinal disease form (but not those with the
hepatosplenic disease form). These Id also are also immunologically stimulatory, inducing T-cell proliferation and differential cytokine production (5, 7). Furthermore, anti-idiotypic sera
produced against Id from human patients with the intestinal form of the disease cross-react with Id produced from the sera of MSS mice (3, 6). We recently demonstrated that injection of
neonatal mice with this cross-reactive Id alters future immune
responses and the development of pathology in mice when they are
subsequently infected with S. mansoni. We believe this may
in part explain the pathological differences in disease development
between persons born to mothers in areas where schistosomiasis is
endemic versus those born where the disease is nonendemic (8,
9). The presence of T-cell-stimulatory cross-reactive Id could
alter the developing immune response, perhaps by their effect on the
T-cell repertoire.
To address this possibility, we investigated whether MSS and HSS
animals display differential T-cell receptor (TCR) V
usage. As the
V
gene product expressed by a given TCR is a major determinant of
the antigen specificity of that T cell, differences in V
TCR usage
could imply that different antigens are being predominantly recognized
or that different regulatory T cells are engaged in the differentiation
of MSS and HSS mice. Male CBA/J mice used in these experiments were
obtained from The Jackson Laboratory, housed in the American
Association for Accreditation of Laboratory Animal Care-approved animal
care facilities of the Centers for Disease Control and Prevention, and
cared for in compliance with institutional guidelines and federal
regulations. Mice were infected by subcutaneous injection of 45 cercariae of a Puerto Rican strain of S. mansoni that had
been maintained in Biomphalaria glabrata snails. At 20 weeks
of infection, animals were sacrificed and classified as having MSS or
HSS, based on percent spleen body weight and gross pathological
appearance. Single-cell suspensions were made from the spleens and
erythrocytes were lysed with a red blood cell lysing buffer (Sigma
Chemical Co., St. Louis, Mo.). Spleen cells were stained with a panel
of fluorescein isothiocyanate-conjugated anti-TCR V
antibodies
(catalogue no. 0143KK; PharMingen, San Diego, Calif.) and
phycoerythrin-conjugated anti-CD3 antibodies (catalogue no.
01085B; PharMingen) according to previously published methods
(3). Flow cytometric data were acquired with a FACScan flow cytometer (Becton-Dickinson, San Jose, Calif.) and analyzed with
Cell Quest software (Becton-Dickinson).
TCR V
usage was calculated as the percent CD3+
cells positive for the various TCR V
markers. MSS and HSS mice (two
to five mice per group) from five different infection dates were used to alleviate any effect that may be peculiar to a given infecting innoculum. An uninfected control mouse was included in each experiment. Percentages of the various TCR V
gene products expressed on
CD3+ cells were averaged, and means were compared
by analysis of variance (ANOVA) with the InStat II statistics package
(GraphPad Software, San Diego, Calif.). Results are presented in Fig.
1. We found significant differences
(P < 0.05) in 11 of 15 V
TCRs tested, with HSS
spleen cells making up a larger percentage of 8 V
TCRs and MSS
spleen cells making up a larger percentage of 3 V
TCRs. Interestingly, for almost every specific V
TCR tested, the
percentage of MSS spleen cells more closely resembled that of the
uninfected mouse spleen cells than that of the HSS spleen cells.
These findings are consistent with those of Vella and Pearce
(10), who found that TCR V
usage among
CD4+ cells of 9-week-infected C57BL/6 mice did
not differ significantly from that of uninfected C57BL/6 mice. One
experiment in this study, in which cells were stained with anti-TCR
V
antibodies and anti-CD4 antibodies, showed a pattern of TCR V
usage in MSS and HSS mice that was similar to, albeit less dramatic
than, that obtained when total T cells were assessed (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Mean percent of CD3 cells positive for various TCR V s
in spleens of noninfected (grey bars, n = 5), MSS
(white bars, n = 17), or HSS (black bars,
n = 15) mice. An asterisk indicates statistical
significance (P < 0.05) in group means as
determined by ANOVA.
|
|
We also performed regression analysis comparing the degree of
splenomegaly in chronically infected mice with the percent
CD3+ cells that were positive for the various
V
TCRs (Table 1). There were
significant correlations between the percent spleen body weight of
individual HSS mice and the percent positive cells for all 11 V
TCRs
that showed differences between means of uninfected, MSS, and HSS
groups of mice by ANOVA as well as 1 additional V
TCR. As these
correlation results are somewhat predictable from the ANOVA, we also
performed correlative analyses within the HSS group alone and found a
significant relationship between the degree of splenomegaly and the
percent positive cells for six V
TCRs. There was a significant
positive correlation for four V
s and a significant inverse
correlation for the other two (Table 1). Positive correlations suggest
preferential expansion of certain V
+ T cells
in response to antigenic stimulation. However, it is not clear whether
the negative correlations represent a selective down-regulation, or
even elimination, of T cells positive for these V
TCRs or are simply
the result of a more prominent expansion by T cells expressing other
V
TCRs.
The variation of TCR V
usage between MSS and HSS animals indicates
that a different T-cell repertoire develops in MSS versus HSS mice and,
by implication, recognition of different antigen sets by these groups
of chronically infected animals. We are currently addressing this
question. We also do not know whether the differences in TCR V
usage
of HSS mice are a cause or effect of the severe pathology in these
animals or whether the thymic atrophy observed in HSS mice is related
to the altered TCR V
usage of these animals. These questions are the
topic of ongoing research.
 |
ACKNOWLEDGMENTS |
This investigation received financial assistance from the
UNDP/World Bank/WHO Special Programme for Research and Training in
Tropical Diseases (TDR).
We also thank Patrick J. Lammie, Daniel G. Colley, and Virginia H. Secor for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Immunology
Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Hwy., NE, MS-F13, Atlanta, GA 30341-3724. Phone: (770) 488-4115. Fax: (770) 488-3115. E-mail:
was4{at}cdc.gov.
Editor:
J. M. Mansfield
 |
REFERENCES |
| 1.
|
Adewusi, O. I.,
N. A. Nix,
X. Lu,
D. G. Colley, and W. E. Secor.
1996.
Schistosoma mansoni: relationship of tumor necrosis factor-alpha to morbidity and collagen deposition in chronic experimental infection.
Exp. Parasitol.
84:115-123[CrossRef][Medline].
|
| 2.
|
Bosshardt, S. C.,
G. L. Freeman, Jr.,
W. E. Secor, and D. G. Colley.
1997.
IL-10 deficit correlates with chronic, severe morbidity in male CBA/J mice infected with Schistosoma mansoni.
Parasite Immunol.
19:347-353[CrossRef][Medline].
|
| 3.
|
Freeman, G. L., Jr.,
M. A. Montesano,
W. E. Secor,
D. G. Colley,
M. J. Howard, and S. C. Bosshardt.
1996.
Immunopathogenesis and immunoregulation in schistosomiasis: distinct chronic pathologic syndromes in CBA/J mice.
Ann. N. Y. Acad. Sci.
797:151-165[CrossRef][Medline].
|
| 4.
|
Henderson, G. S.,
N. A. Nix,
M. A. Montesano,
D. Gold,
G. Freeman,
T. L. McCurley, and D. G. Colley.
1993.
Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni infections.
Am. J. Pathol.
142:703-714[Abstract].
|
| 5.
|
Montesano, M. A.,
M. S. Lima,
R. Correa-Oliveira,
G. Gazzinelli, and D. G. Colley.
1989.
Immune responses during human schistosomiasis mansoni. XVI. Idiotypic differences in antibody preparations from patients with different clinical forms of infection.
J. Immunol.
142:2501-2506[Abstract].
|
| 6.
|
Montesano, M. A.,
G. L. Freeman, Jr.,
G. Gazzinelli, and D. G. Colley.
1990.
Expression of cross-reactive, shared idiotypes on anti-SEA antibodies from humans and mice with schistosomiasis.
J. Immunol.
145:1002-1008[Abstract].
|
| 7.
|
Montesano, M. A.,
G. L. Freeman,
W. E. Secor, and D. G. Colley.
1997.
Immunoregulatory idiotypes stimulate T helper 1 cytokine responses in experimental Schistosoma mansoni infections.
J. Immunol.
158:3800-3804[Abstract].
|
| 8.
|
Montesano, M. A.,
D. G. Colley,
S. Eloi-Santos,
G. L. Freeman, Jr., and W. E. Secor.
1999.
Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections.
J. Exp. Med.
189:637-645[Abstract/Free Full Text].
|
| 9.
|
Montesano, M. A.,
D. G. Colley,
G. L. Freeman, Jr., and W. E. Secor.
1999.
Neonatal exposure to idiotype induces Schistosoma mansoni egg antigen specific cellular and humoral immune responses.
J. Immunol.
163:898-905[Abstract/Free Full Text].
|
| 10.
|
Vella, A. T., and E. J. Pearce.
1993.
CD4+ T-cell receptor V usage during the immune response to Schistosoma mansoni.
Infect. Immun.
61:5381-5383[Abstract/Free Full Text].
|
Infection and Immunity, June 2001, p. 4177-4179, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.4177-4179.2001